AstraZeneca (NYSE:AZN) Sees Unusually-High Trading Volume

AstraZeneca PLC (NYSE:AZNGet Rating) saw an uptick in trading volume on Monday . 197,491 shares changed hands during trading, a decline of 97% from the previous session’s volume of 7,291,165 shares.The stock last traded at $63.65 and had previously closed at $65.70.

Separately, StockNews.com raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Tuesday, May 10th.

The business’s fifty day moving average price is $66.46.

AstraZeneca (NYSE:AZNGet Rating) last posted its earnings results on Friday, April 29th. The company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.86 by $0.09. The company had revenue of $11.39 billion for the quarter, compared to analysts’ expectations of $11.19 billion.

About AstraZeneca (NYSE:AZN)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Further Reading

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.